Cue Biopharma

86 articles with Cue Biopharma

• Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

  1/20/2022

  Cue Biopharma, Inc. announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST.

• Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

  1/5/2022

  Cue Biopharma, Inc. (Nasdaq: CUE), along with LG Chem Life Sciences, announced today that a key milestone in the selection of a clinical product candidate has been reached in their collaboration for CUE-102, an Immuno-STAT™ biologic, jointly developed to selectively target WT1-expressing cancers.

• 

  BioSpace Movers & Shakers, Dec. 17

  12/17/2021

  As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers.

• Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

  12/15/2021

  Cue Biopharma, Inc. announced the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15th, 2021.

• Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit

  12/6/2021

  Cue Biopharma, Inc. announced today that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday, December 6, 11:40 a.m. – 12:10 p.m. EST.

• Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

  11/22/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

  11/12/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), announced today the presentation of interim data further demonstrating the tolerability and antitumor activity potential of CUE-101 as a monotherapy as part of the Company’s ongoing clinical trial for the treatment of recurrent/metastatic HPV+ head and neck cancer in a poster at the Society for Immunotherapy of Cancer's 36th Annual Meeting.

• Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November 2021

  11/10/2021

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19.

• Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases

  10/21/2021

  Cue Biopharma, Inc. announced today the publication of a research study titled “ T-Cell Receptor-specific Immunotherapeutics Drive Selective In vivo HIV and CMV- specific T-Cell Expansion in Humanized Mice ” in the peer-reviewed Journal of Chronic Infectious Diseases.

• Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting

  10/4/2021

  Cue Biopharma, Inc. (NASDAQ: CUE), announced today three poster presentations at the Society for Immunotherapy of Cancer's 36th Anniversary Annual Meeting (SITC 2021), to be held both in Washington, D.C. at the Walter E. Washington Convention Center and virtually November 10-14, 2021.

• Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

  9/28/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the publication of research titled “Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells” in the peer-reviewed Nature journal, Scientific Reports.

• Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio

  9/21/2021

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body, announced today the issuance of two new United States Patents Nos. 11,117,945 and 11,104,712 from the United States Patent and Trademark Office.

• Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

  9/9/2021

  Cue Biopharma, Inc. announced today that it will take part in two fireside chats, Baird's 2021 Global Healthcare Conference, September 14-15 and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20-23, 2021.

• Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

  8/17/2021

  Cue Biopharma, Inc. provided a business and clinical progress update for the second quarter 2021.

• Cue Biopharma to Host Business Update Call and Webcast - Aug 10, 2021

  8/10/2021

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced it will host a conference call and webcast to provide a business update on Tuesday, August 17, 2021 at 4:30 p.m. EDT.

• Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference

  8/3/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.

• Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

  6/14/2021

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021.

• Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

  6/10/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg.

• Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

  6/3/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting , which is being held virtually from June 8-11, 2021.

• Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference

  5/26/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the Jefferies Virtual Healthcare Conference being held June 1-4, 2021.